

**New Jersey Drug Utilization Review Board
Virtual Platform
October 22, 2025**

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of meeting transcript for July 16, 2025, meeting
https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/10-2025/July-2025_DURB_Meeting_Transcript.pdf
- IV. Review of draft meeting summary for July 16, 2025, meeting (pages 3-7)
- V. Secretary's report (page 8)
- VI. Old Business
 - A. Utilization Trends of SGLT-2 inhibitors (pages 9-10)
 - B. Utilization Trends of GLP-1/GIP Agonists (pages 11-12)
 - C. Updated Protocol for Imcivree® (pages 13-15)
 - D. Updated Protocol for Chimeric Antigen Receptor (CAR) T Cell Products (pages 16-19)
 - E. Updated Protocol for Paroxysmal Nocturnal Hemoglobinuria (PNH) Products (pages 20-22)
- VII. New Business
 - A. Proposed Addendum to Protocol for Biologics in Moderate to Severe Asthma (pages 23-25)
 - B. Proposed Addendum to Protocol for Dupixent® (pages 26-30)
 - C. Proposed Addendum to Protocol for Hereditary Angioedema (pages 31-33)
 - D. Proposed Addendum to Protocol for Wegovy® (pages 34-35)

VIII. A. Informational Highlights/Reports

1. Gainwell Technologies/NJ MCO 2nd Quarter 2025 Prior Authorization Report (page 36)
2. Summary of DURB Action Items (pages 37-41)
3. DHS/DOH Pharmacy Programs Top Drugs Report/Physicians Administered Drugs Report (by amount paid and by category):

FFS top drugs:

http://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/10-2025/FFS_Top_Drugs_Report_July-2025.pdf

MCO top drugs:

https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/10-2025/MCO_Top_Drugs_Report_June-2025.pdf

FFS top drugs by category:

https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/10-2025/FFS_Top_Drugs_by_Category_July-2025.pdf

MCO top drugs by category:

https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/10-2025/MCO_Top_Drugs_by_Category_June-2025.pdf

FFS antiviral drugs:

https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/10-2025/FFS_Antiviral_Drugs_July-2025.pdf

B. Medication/Medical information

[American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia - Endocrine Practice](#)

[New AACE 2025 Dyslipidemia Management Guidelines Released – Top 7 Takeaways](#)

https://www.jacc.org/doi/10.1016/j.jacc.2025.05.007?_gl=1*1uisott*_ga*NTM2MjMwMTIuMTc1NTYxNjMwMw.*_ga_2V8VW4Y237*cze3NTU2MTYzMDIkbzEkZzEkdDE3NTU2MTYzNDYkajE2JGwwJGgw